Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Simcere Zaiming, Inc. (Last) (First) (Middle) 20 ACORN PARK DR. (Street) CAMBRIDGE MA 02140 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/20/2025	3. Issuer Name and Ticker or Trading Symbol NextCure, Inc. [ NXTC ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	338,636	I	See footnotes(1)(2)(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming" or the "Reporting Person") and may be deemed to be indirectly beneficially owned by the other persons.

2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote.

3. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that the Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

	Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.